Colorectal Cancer (CRC) Recruiting Phase 1 Trials for Cisplatin (DB00515)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04329494	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	Treatment	Cisplatin (DB00515) Doxorubicin (DB00997) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Mitomycin (DB00305) Oxaliplatin (DB00526) Platinum (DB12257)
NCT04847063	Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies	Diagnostic	Cisplatin (DB00515) Doxorubicin (DB00997) Fluorouracil (DB00544) Leucovorin (DB00650) Mitomycin (DB00305) Oxaliplatin (DB00526) Thiosulfuric acid (DB09499)
NCT06621563	Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors	Treatment	Capecitabine (DB01101) Cisplatin (DB00515) Fluorouracil (DB00544) HS-20117 (DB23695) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Pemetrexed (DB00642) Platinum (DB12257) Risvutatug rezetecan (DB23560)
NCT06428409	A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)	Treatment	Acetaminophen (DB00316) Cisplatin (DB00515) Dexamethasone (DB01234) Diphenhydramine (DB01075) Fluorouracil (DB00544) Leucovorin (DB00650) Pembrolizumab (DB09037) Sacituzumab tirumotecan (DB18777)
NCT04999761	AB122 Platform Study	Treatment	Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Domvanalimab (DB18848) Fluorouracil (DB00544) Futibatinib (DB15149) Gemcitabine (DB00441) Paclitaxel (DB01229) Pamufetinib (DB20752) Pimitespib (DB14876) Ramucirumab (DB05578) Zimberelimab (DB17505)
NCT03965234	Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases	Treatment	Cisplatin (DB00515) Platinum (DB12257)
NCT06917079	BBO-11818 in Adult Subjects With KRAS Mutant Cancer	Treatment	BBO-10203 (DB23219) BBO-11818 (DB23520) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642) Platinum (DB12257)
NCT06835569	A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations	Treatment	ALTA3263 (DB23814) Carboplatin (DB00958) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Midazolam (DB00683) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)
NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	Treatment	Carboplatin (DB00958) Cetuximab (DB00002) Cisplatin (DB00515) Daraxonrasib (DB22308) Ivonescimab (DB18931) Pemetrexed (DB00642) Zoldonrasib (DB32223)